Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Initiation Research Report Radiopharm (ASX:RAD) Near to market imaging drug

Thursday, March 14, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for its imaging drug, BetaBart (RV-01). The company has also received IND approval from the US FDA to begin therapeutic studies targeting B7H3. Positive updates have been shared regarding multiple programs, indicating progress in their clinical pipeline.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has initiated a Phase 1/2a clinical study.
  • The company has received IND approval from the US FDA.
  • Positive clinical updates have been reported across four programs.

Full Press Release Details

• Updates
• PDF
• March 14, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• February 6, 2024
• Announcements
• February 12, 2022
• Announcements
• January 24, 2024
• Announcements
• October 26, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the BetaBart clinical study about?

The BetaBart clinical study is a Phase 1/2a trial initiated by Radiopharm Theranostics.

What approval did Radiopharm receive from the FDA?

Radiopharm received IND approval from the US FDA to initiate therapeutic studies targeting B7H3.

When was the first patient dosed in the study?

The first patient was dosed in the Phase 1/2a clinical study of BetaBart.

What updates has Radiopharm provided?

Radiopharm has provided positive clinical updates across four of its programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm BetaBart Phase 1/2a FDA IND approval clinical study
Last updated: Mar 14, 2024